Lawrence Steinman's Stock Option Award in Pasithea Therapeutics Corp.

Lawrence Steinman, a director of Pasithea Therapeutics Corp., was awarded 242,913 stock options on October 24, 2025, with an exercise price of $0.715 per share. The options, which are set to expire on October 23, 2035, will fully vest on the one-year anniversary of the grant date, provided Steinman remains a director through that date. Additionally, the options will fully vest upon a Change in Control as defined in the company's 2023 Stock Incentive Plan. This transaction was reported under Form 4 and is in accordance with the terms of the Plan.